Premier Alternatives

BlossomHill Therapeutics

San Diego, CA · Founded 2020 · Privately Held (backing)

Operator of a biopharmaceutical company designed to develop treatments for oncology and autoimmune diseases. BlossomHill Therapeutics is based in San Diego, CA and was founded in 2020. It was valued at $413 million at its later-stage round in Dec 2025, the last priced event on record. It has raised $257 million across 4 recorded rounds; the latest was an $84.2 million later-stage round in Nov 2025.

PMV mark · valuation
$413.1M
Oct 2026
Priced at
its later-stage round
Dec 2025
Total raised
$257.1M
Last round
Later Stage VC
Nov 2025

BlossomHill Therapeutics key facts

as of Oct 2026
  • Operator of a biopharmaceutical company designed to develop treatments for oncology and autoimmune diseases.
  • BlossomHill Therapeutics is valued at approximately $413.1M as of Oct 2026, set at its later-stage round, Dec 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $257.1M across 4 recorded rounds; the latest was Later Stage VC ($84.2M) in Nov 2025.
  • Notable investors include OrbiMed, Cormorant Asset Management, Vivo Capital, BioTrack Capital, Brahma Capital (Texas) — 10 tracked in total.
  • BlossomHill Therapeutics has filed 4 Form Ds with the SEC since 2021, most recently Dec 2025 ($84.2M sold to 47 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$413.1M

Valued at $413.1M at its later-stage round, Dec 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of BlossomHill Therapeutics with a free account
  • ·Watch BlossomHill Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

BlossomHill Therapeutics funding rounds

4 rounds
Nov 2025Later Stage VC$84.2MSEC filing▮
Dec 2023Later Stage VC$88.6MSEC filing▮
Mar 2021Later Stage VC$71.0MSEC filing▮
Dec 2020Seed Round$2.0MSEC filing▮
Full funding history →

BlossomHill Therapeutics valuation

BlossomHill Therapeutics was valued at $413 million at its later-stage round in Dec 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has BlossomHill Therapeutics raised?

BlossomHill Therapeutics has raised $257 million across 4 recorded rounds since 2020. The largest was an $88.6 million later-stage round in Dec 2023; the most recent was an $84.2 million later-stage round in Nov 2025.

BlossomHill Therapeutics has filed 4 Form Ds with the SEC since 2021, most recently in Dec 2025 ($84.2 million sold to 47 investors).

BlossomHill Therapeutics investors

10 investors are on record for BlossomHill Therapeutics, including OrbiMed, Cormorant Asset Management, Vivo Capital and BioTrack Capital. The later-stage round in Nov 2025 drew 47 investors.

About BlossomHill Therapeutics

Operator of a biopharmaceutical company designed to develop treatments for oncology and autoimmune diseases. The company offers innovative drug design expertise and precision medicine approaches, enabling patients with challenging medical conditions to access therapies addressing resistance mechanisms in current treatments.

Sector
Healthcare
HQ
San Diego, CA, United States
Founded
2020
Employees
55
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.